AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (AVXL) is expected to report earnings on October 29, 2026, before the market open. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +28.3% since its last earnings release on July 30, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer.
Sector
Healthcare
Industry
Biotechnology